Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)

NCT01800968 · Completed

Last updated 2026-05-28

The FIGHT trial tested whether a medication called GLP-1 could help people hospitalized with acute heart failure.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 300 people

Who can join Ages 18+ · all sexes

Timeline Started 2013-04 · est. completion 2015-10

Where 25 sites · United States

What this study is testing ClinicalTrials.gov NCT01800968 ↗

Description as written by the study sponsor.

The primary objective is to test the hypothesis that, compared with placebo, therapy with Subcutaneous (SQ) GLP-1 agonist in the post-Acute Heart Failure Syndrome (AHFS) discharge period will be associated with greater clinical stability at six months as assessed by a composite clinical endpoint.

Treatments tested

Liraglutide also known as Victoza Drug

Active Drug
Placebo Drug

Placebo

Main thing measured	Global Ranking of Predefined Events
Sponsor	Duke University
Conditions studied	Acute Heart Failure
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01800968 ↗